Institution
National Multiple Sclerosis Society
Nonprofit•New York, New York, United States•
About: National Multiple Sclerosis Society is a nonprofit organization based out in New York, New York, United States. It is known for research contribution in the topics: Multiple sclerosis & Clinical trial. The organization has 102 authors who have published 160 publications receiving 20830 citations. The organization is also known as: National MS Society.
Papers published on a yearly basis
Papers
More filters
Royal College of Physicians1, University of Cambridge2, University of California, San Francisco3, University of Graz4, Icahn School of Medicine at Mount Sinai5, National Institutes of Health6, University of British Columbia7, VU University Amsterdam8, National Multiple Sclerosis Society9, Lund University10, University of Arizona11, University College London12, University of California, Irvine13, Mayo Clinic14, University of Texas Health Science Center at Houston15
TL;DR: The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.
Abstract: The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in both time and space. Magnetic resonance imaging is integrated with dinical and other paraclinical diagnostic methods. The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including "monosymptomatic" disease suggestive of MS, disease with a typical relapsing-remitting course, and disease with insidious progression, without clear attacks and remissions. Previously used terms such as "clinically definite" and "probable MS" are no longer recommended. The outcome of a diagnostic evaluation is either MS, "possible MS" (for those at risk for MS, but for whom diagnostic evaluation is equivocal), or "not MS."
6,720 citations
University College London1, Children's Hospital of Philadelphia2, VU University Medical Center3, Sir Charles Gairdner Hospital4, National Multiple Sclerosis Society5, Vita-Salute San Raffaele University6, Medical University of Graz7, Ottawa Hospital Research Institute8, Fukushima Medical University9, New York University10, University of Düsseldorf11, University of Basel12, Corinne Goldsmith Dickinson Center for Multiple Sclerosis13, University of Manitoba14, Hebron University15, St. Michael's Hospital16, Johns Hopkins University17, University of Copenhagen18, University of British Columbia19, University of Bari20, French Institute of Health and Medical Research21, Claude Bernard University Lyon 122, University of California, San Francisco23, Mayo Clinic24, Salisbury University25, Cleveland Clinic26
TL;DR: The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation.
Abstract: The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research and clinical practice. Scientific advances in the past 7 years suggest that they might no longer provide the most up-to-date guidance for clinicians and researchers. The International Panel on Diagnosis of Multiple Sclerosis reviewed the 2010 McDonald criteria and recommended revisions. The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation. The following changes were made: in patients with a typical clinically isolated syndrome and clinical or MRI demonstration of dissemination in space, the presence of CSF-specific oligoclonal bands allows a diagnosis of multiple sclerosis; symptomatic lesions can be used to demonstrate dissemination in space or time in patients with supratentorial, infratentorial, or spinal cord syndrome; and cortical lesions can be used to demonstrate dissemination in space. Research to further refine the criteria should focus on optic nerve involvement, validation in diverse populations, and incorporation of advanced imaging, neurophysiological, and body fluid markers.
3,945 citations
Icahn School of Medicine at Mount Sinai1, Cleveland Clinic2, University of Alabama at Birmingham3, University of Copenhagen4, University College London5, University of Texas Health Science Center at Houston6, New York University7, University of Pennsylvania8, VU University Amsterdam9, National Multiple Sclerosis Society10, Johns Hopkins University11, Vita-Salute San Raffaele University12, University of Ottawa13, University of Rochester14, University of Basel15, University of Düsseldorf16, Pierre-and-Marie-Curie University17, Autonomous University of Barcelona18, University of Toronto19, University of British Columbia20, Sapienza University of Rome21, University of Texas Southwestern Medical Center22, University of California, San Francisco23
TL;DR: Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.
Abstract: Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
2,180 citations
Anschutz Medical Campus1, Cleveland Clinic2, University at Buffalo3, University of British Columbia4, Veterans Health Administration5, Mayo Clinic6, McGill University7, University of California, Los Angeles8, Drexel University9, Maimonides Medical Center10, Medical College of Wisconsin11, National Multiple Sclerosis Society12, Auckland City Hospital13
TL;DR: A composite measure encompassing the major clinical dimensions of arm, leg and cognitive function was identified and termed the multiple sclerosis functional composite (MSFC), suggesting that the MSFC is more sensitive to change than the EDSS.
Abstract: The primary clinical outcome measure for evaluating multiple sclerosis in clinical trials has been Kurtzke's expanded disability status scale (EDSS). New therapies appear to favourably impact the course of multiple sclerosis and render continued use of placebo control groups more difficult. Consequently, future trials are likely to compare active treatment groups which will most probably require increased sample sizes in order to detect therapeutic efficacy. Because more responsive outcome measures will be needed for active arm comparison studies, the National Multiple Sclerosis Society's Advisory Committee on Cinical Trials of New Agents in Multiple Sclerosis appointed a Task Force that was charged with developing improved clinical outcome measures. This Task Force acquired contemporary clinical trial and historical multiple sclerosis data for meta-analyses of primary and secondary outcome assessments to provide a basis for recommending a new outcome measure. A composite measure encompassing the major clinical dimensions of arm, leg and cognitive function was identified and termed the multiple sclerosis functional composite (MSFC). The MSFC consists of three objective quantitative tests of neurological function which are easy to administer. Change in this MSFC over the first year of observation predicted subsequent change in the EDSS, suggesting that the MSFC is more sensitive to change than the EDSS. This paper provides details concerning the development and testing of the MSFC.
1,125 citations
TL;DR: There are many differences between men and women in their susceptibility to particular autoimmune diseases, the characteristics of the disease at onset, and disease severity as mentioned in this paper, and they discuss priorities for future research.
Abstract: There are many differences between men and women in their susceptibility to particular autoimmune diseases, the characteristics of the disease at onset, and disease severity. In a Perspective in this issue, Caroline Whitacre and her fellow members of the Task Force on Gender, Multiple Sclerosis and Autoimmunity explain what we currently know about gender differences in autoimmunity and discuss priorities for future research.
779 citations
Authors
Showing all 102 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Douglas L. Arnold | 100 | 624 | 37040 |
| Stephen M. Rao | 78 | 237 | 26994 |
| John DeLuca | 72 | 316 | 16588 |
| Gary M. Franklin | 61 | 206 | 12788 |
| Richard P. Bunge | 58 | 112 | 10297 |
| Jens Kuhle | 57 | 280 | 11767 |
| Finn Sellebjerg | 55 | 292 | 14187 |
| David Leppert | 47 | 148 | 8410 |
| Jeffrey M. Gelfand | 38 | 118 | 6368 |
| Stephen C. Reingold | 37 | 68 | 34843 |
| Nicholas G. LaRocca | 36 | 71 | 10230 |
| Bruce F. Bebo | 35 | 54 | 6527 |
| Kathleen M. Zackowski | 23 | 49 | 2120 |
| Tatiana Plavina | 22 | 51 | 2739 |
| Charity Evans | 19 | 52 | 1209 |